Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Vorinostat (Suberoylanilide hydroxamic acid, SAHA) provides prolonged clinical benefit to advanced cutaneous T-Cell lymphoma patients: Updated results of the phase IIb multicenter clinical trial. Duvic, M., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J., Randolph, S., Richon, V. M., Olsen, E. A. AMER SOC HEMATOLOGY. 2006: 122A
View details for Web of Science ID 000242440000400